Trastuzumab | Lapatinib | P-value | |
---|---|---|---|
N = 381 | N = 262 | ||
Number of days between the index date and the end of the study period, mean ± SD | 453.3 ± 334.0 | 412.9 ± 327.1 | 0.123 |
Treatment duration (i.e. the number of days between the index date and treatment discontinuation or the end of the study period), mean ± SD | 269.1 ± 235.1 | 179.8 ± 189.0 | < 0.001** |
Cancer treatments used during the study period, N (%) | |||
Hormonal therapy | 110 (28.9) | 25 (9.5) | < 0.001** |
Radiation therapy | 168 (44.1) | 114 (43.5) | 0.884 |
Surgery (mastectomy) | 33 (8.7) | 2 (0.8) | < 0.001** |
Chemotherapy or anti-angiogenic therapy, N (%) | |||
Any chemotherapy or anti-angiogenic therapya | 320 (84.0) | 228 (87.0) | 0.287 |
Capecitabine | 71 (18.6) | 194 (74.0) | < 0.001** |
Paclitaxel | 156 (40.9) | 48 (18.3) | < 0.001** |
Docetaxel | 112 (29.4) | 21 (8.0) | < 0.001** |
Carboplatin | 103 (27.0) | 25 (9.5) | < 0.001** |
Vinorelbine | 86 (22.6) | 40 (15.3) | 0.022** |
Gemcitabine | 51 (13.4) | 26 (9.9) | 0.184 |
Bevacizumab | 29 (7.6) | 28 (10.7) | 0.178 |
Doxorubicin | 38 (10.0) | 21 (8.0) | 0.398 |
Cyclophosphamide | 39 (10.2) | 12 (4.6) | 0.009** |
Fluorouracil | 17 (4.5) | 5 (1.9) | 0.080 |
Ixabepilone | 15 (3.9) | 15 (5.7) | 0.291 |
Epirubicin | 8 (2.1) | 0 (0.0) | - |
Cisplatin | 2 (0.5) | 3 (1.1) | 0.379 |
Mitoxantrone | 1 (0.3) | 1 (0.4) | 0.790 |
Etoposideb | 0 (0.0) | 0 (0.0) | - |
Vinblastineb | 0 (0.0) | 0 (0.0) | - |
Any chemotherapy or anti-angiogenic therapy within 28 days following the index date | 285 (74.8) | 193 (73.7) | 0.745 |